Cutaneous Lupus Erythematosus is a chronic, autoimmune disease affecting the skin, which belongs to the family of lupus erythematosus where the symptoms are restricted to the skin.
Cutaneous Lupus Erythematosus Epidemiology Insights
- The total prevalent population of Cutaneous Lupus Erythematosus in 7MM in 2017 was 327,569
- Cutaneous Lupus Erythematosus cases in the United States in 2017 was 182,765
-
The prevalent cases of Chronic Cutaneous Lupus Erythematosus (CCLE) in the US in 2017 was 92,662
- The prevalent cases of Cutaneous Lupus Erythematosus in the US in 2017
- 71,279- Men
- 111,487 – Women
Cutaneous Lupus Erythematosus Market
Cutaneous Lupus Erythematosus Market Size in 7MM in 2017 was USD 485.27 Million
Cutaneous Lupus Erythematosus Market Drivers
- Rising Prevalence and Awareness of the disease
- Refined clinical trial design
- Contemporary advances in R&D
Cutaneous Lupus Erythematosus Market Barriers
- Limited translation of therapies into real world
- Lack of subtype specific therapies
1. Key Insights
2. Executive Summary of Cutaneous Lupus Erythematosus
3. Competitive Intelligence Analysis for Cutaneous Lupus Erythematosus
4. Cutaneous Lupus Erythematosus : Market Overview at a Glance
4.1. Cutaneous Lupus Erythematosus Total Market Share (%) Distribution in 2017
4.2. Cutaneous Lupus Erythematosus Total Market Share (%) Distribution in 2030
5. Cutaneous Lupus Erythematosus : Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Cutaneous Lupus Erythematosus Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Cutaneous Lupus Erythematosus Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Cutaneous Lupus Erythematosus Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Cutaneous Lupus Erythematosus Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Cutaneous Lupus Erythematosus Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Cutaneous Lupus Erythematosus Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Cutaneous Lupus Erythematosus Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Cutaneous Lupus Erythematosus Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Cutaneous Lupus Erythematosus Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Cutaneous Lupus Erythematosus Treatment and Management
8.2. Cutaneous Lupus Erythematosus Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Cutaneous Lupus Erythematosus Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Cutaneous Lupus Erythematosus : Seven Major Market Analysis
13.1. Key Findings
13.2. Cutaneous Lupus Erythematosus Market Size in 7MM
13.3. Cutaneous Lupus Erythematosus Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Cutaneous Lupus Erythematosus Total Market Size in the United States
15.1.2. Cutaneous Lupus Erythematosus Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Cutaneous Lupus Erythematosus Total Market Size in Germany
15.3.2. Cutaneous Lupus Erythematosus Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Cutaneous Lupus Erythematosus Total Market Size in France
15.4.2. Cutaneous Lupus Erythematosus Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Cutaneous Lupus Erythematosus Total Market Size in Italy
15.5.2. Cutaneous Lupus Erythematosus Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Cutaneous Lupus Erythematosus Total Market Size in Spain
15.6.2. Cutaneous Lupus Erythematosus Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Cutaneous Lupus Erythematosus Total Market Size in the United Kingdom
15.7.2. Cutaneous Lupus Erythematosus Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Cutaneous Lupus Erythematosus Total Market Size in Japan
15.8.3. Cutaneous Lupus Erythematosus Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Cutaneous Lupus Erythematosus
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/